T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness

Clinical Cancer Research

Volumn 20, Issue 18, 2014, Pages 4949-4961

  Pinto, Filipe ^a,b   Pértega Gomes, Nelma ^a,b   Pereira, Márcia S ^a,b   Vizcaíno, José R ^c   Monteiro, Pedro ^d   Henrique, Rui M ^e,f   Baltazar, Fátima ^a,b   Andrade, Raquel P ^a,b   Reis, Rui M ^a,b,g  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c Centro Hospitalar Universitario do Porto   (Portugal)

^d Centro Hospitalar Do Alto Ave Guimarães   (Portugal)

^e PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

^g BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYURY PROTEIN; FETOPROTEIN; T BOX TRANSCRIPTION FACTOR; TUMOR MARKER;

ADENOCARCINOMA; AGED; BIOSYNTHESIS; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; BLOTTING, WESTERN; CELL LINE, TUMOR; FETAL PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-BOX DOMAIN PROTEINS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84907916641     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0421     Document Type: Article

References (44)

1. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010;46:3040-52.
2. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
3. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14: 818-29.
4. Technau U, Scholz CB. Origin and evolution of endoderm and mesoderm. Int J Dev Biol 2003;47:531-9.
5. Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006;209:157-65.
6. Haro A, Yano T, Kohno M, Yoshida T, Koga T, Okamoto T, et al. Expression of brachyury gene is a significant prognostic factor for primary lung carcinoma. Ann Surg Oncol 2013;20 Suppl 3: S509-16.
7. Imajyo I, Sugiura T, Kobayashi Y, Shimoda M, Ishii K, Akimoto N, et al. T-box transcription factor Brachyury expression is correlated with epithelial-mesenchymal transition and lymph node metastasis in oral squamous cell carcinoma. Int J Oncol 2012;41:1985-95.
8. Kilic N, Feldhaus S, Kilic E, Tennstedt P, Wicklein D, Wasielewski Rv, et al. Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer 2011;47:1080-5.
9. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res 2012;18:3868-79.
10. Sarkar D, Shields B, Davies ML, Müller J, Wakeman JA. BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells. Int J Cancer 2012;130:328-37.
11. Shimoda M, Sugiura T, Imajyo I, Ishii K, Chigita S, Seki K, et al. The Tbox transcription factor Brachyury regulates epithelial-mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cells. BMC Cancer 2012;12:377.
12. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelialmesenchymal transition in human tumor cells. J Clin Invest 2010; 120:533-44.
13. Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH, Palena C. An autocrine loop between TGF-beta1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype. Mol Cancer Ther 2013;12:1805-15.
14. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 2011;71:5296-306.
15. Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, et al. The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death Dis 2013;4:e682.
16. Park JC, Chae YK, Son CH, KimMS, Lee J, Ostrow K, et al. Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochem Biophys Res Commun 2008;365:221-6.
17. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. Chicago, IL: Springer; 2010.
18. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LLISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
19. P-ertega-Gomes N, Vizcaíno JR, Gouveia C, Jer-onimo C, Henrique RM, Lopes C, et al. Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate 2013;73:763-9.
20. Martinho O, Pinto F, Granja S, Miranda-Goncalves V, Moreira MA, Ribeiro LF, et al. RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy. PLoS One 2013;8:e59104.
21. Moniz S, Martinho O, Pinto F, Sousa B, Loureiro C, Oliveira MJ, et al. Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness. Hum Mol Genet 2013;22:84-95.
22. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002;62:4499-506.
23. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
24. GrassoCS,WuYM, Robinson DR, Cao X, DhanasekaranSM, KhanAP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-43.
25. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
26. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113:913-23.
27. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22: 2790-9.
28. The Cancer Genome Atlas (TCGA). [cited 2013 Nov 30] Available from: https://tcga-data.nci.nih.gov/tcga/.
29. Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res 2009;15:5794-802.
30. Oncomine. Ann Arbor, MI:Compendia Bioscience.-2007-2010 [cited 2013 Nov 30]. Available from: https://www.oncomine.org.
31. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007; 9:166-80
32. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
33. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1-13.
34. Wilkinson DG, Bhatt S, Herrmann BG. Expression pattern of the mouse T gene and its role in mesoderm formation. Nature 1990;343:657-9.
35. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 2013;4:e875.
36. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 2007;13:2471-8.
37. Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, et al. Immunological targeting of tumor cells undergoing an epithelialmesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 2013;4:1777-90.
38. Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 2013;13:788-99.
39. Sottnik JL, Zhang J, Macoska JA, Keller ET. The PCa tumor microenvironment. Cancer Microenviron 2011;4:283-97.
40. Wang X, Lee SO, Xia S, Jiang Q, Luo J, Li L, et al. Endothelial cells enhance prostate cancer metastasis via IL-6-androgen receptor-TGF-beta-MMP-9 signals. Mol Cancer Ther 2013;12: 1026-37.
41. Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, et al. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol 2011;223: 327-35.
42. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
43. Hao J, Madigan MC, Khatri A, Power CA, Hung TT, Beretov J, et al. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS One 2012;7:e40716.
44. Xiao W, Graham PH, Power CA, Hao J, Kearsley JH, Li Y. CD44 is a biomarker associated withhuman prostate cancer radiation sensitivity. Clin Exp Metastasis 2012;29:1-9.